ArticleInternational journal of molecular sciences2026
Endothelin-1 and Anticardiolipin Antibodies in Primary Biliary Cholangitis Patients with Portal Hypertension: A Pilot Retrospective Study.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune, cholestatic liver disease leading to fibrosis, cirrhosis, and portal hypertension. Endothelin-1 (ET-1), a potent vasoconstrictor with profibrotic properties, has been implicated in the pathogenesis of liver fibrosis and portal hypertension. Anti-cardiolipin antibodies (aCL) may further contribute to disease progression by promoting thrombotic complications. Our aim was to evaluate serum ET-1 concentrations and anti-cardiolipin antibody levels in PBC patients and their association with portal hypertension. Serum samples from 80 patients with PBC, including patients with portal hypertension, and 25 healthy controls were analyzed. ET-1 concentrations and anti-cardiolipin antibodies were measured using commercially available immunoassays. Elevated serum ET-1 levels were detected in 84% of patients with PBC and portal hypertension and the ET-1 concentrations were also significantly higher in this group compared to the control group. Serum ET-1 levels positively correlated with total bilirubin concentrations and the severity of histological fibrosis. Anti-cardiolipin antibodies were detected in 32% of PBC patients with portal hypertension. Elevated serum ET-1 concentrations and the presence of anti-cardiolipin antibodies are associated with advanced liver disease and portal hypertension in patients with PBC. These biomarkers may have potential value in identifying patients at increased risk of disease progression and worsening liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.